Maryll Toufanian, JD, Acting Director, US FDA Office of Generic Drug Policy, discusses the US FDA’s <a href="https://blogs.fda.gov/fdavoice/index.php/2017/06/fda-working-to-lift-barriers-to-generic-drug-competition/" target="_blank">Drug Competition Action Plan</a>, why US consumers can feel safe taking generic drugs, and how generic drugs can help reduce costs for healthcare patients and systems. Learn more at our <a href="http://www.diaglobal.org/en/conference-listing/meetings/2018/10/complex-drug-device-generic-combination-products" target="_blank">Complex Drug-Device Generic Combination Products</a> conference.

Maryll Toufanian, JD, Acting Director, US FDA Office of Generic Drug Policy, discusses the US FDA’s Drug Competition Action Plan, why US consumers can feel safe taking generic drugs, and how generic drugs can help reduce costs for healthcare patients and systems. Learn more at our Complex Drug-Device Generic Combination Products conference.

Maryll Toufanian, JD, Acting Director, US FDA Office of Generic Drug Policy, discusses the US FDA’s <a href="https://blogs.fda.gov/fdavoice/index.php/2017/06/fda-working-to-lift-barriers-to-generic-drug-competition/" rel="noopener noreferrer">Drug Competition Action Plan</a>, why US consumers can feel safe taking generic drugs, and how generic drugs can help reduce costs for healthcare patients and systems.&nbsp;Learn more at our <a href="http://www.diaglobal.org/en/conference-listing/meetings/2018/10/complex-drug-device-generic-combination-products" rel="noopener noreferrer">Complex Drug-Device Generic Combination Products</a> conference.

US Generic Drug Policy: Less Cost, Same Impact

DIA is a global, multidisciplinary, membership association of healthcare professionals that works towards the advancement of lifesaving medicines, therapies, and technologies around the world.

Share US Generic Drug Policy: Less Cost, Same Impact

Sign up to save your podcasts

US Generic Drug Policy: Less Cost, Same Impact

US Generic Drug Policy: Less Cost, Same Impact